The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024 Beijing Time ( 8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be ...

在国家自然科学基金项目（批准号：82072784、82072785、82273304、82303437）等资助下，复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...

The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...

The approval is based on the Phase II LITESPARK-004 trial's objective response rate and median duration of response outcomes.

The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...

Akeso is awaiting approval from China's medicines regulator for a penpulimab-anlotinib combination therapy for advanced liver ...